Breast cancer: understanding etiology, addressing molecular signaling pathways, identifying therapeutic targets and strategizing the treatment
Article Sidebar
-
Breast Cancer, Classification of Breast Cancer, Enzymes, Etiology, Genetic Mutations, Non-Coding RNAs, Signaling Pathway
Abstract
Breast cancer has messed the life of a greater number of women being the most common cancer affecting them worldwide. A number of risk factors contribute the breast malignancy, however, genetic drift is accountable the most. Depending on the cell origin, invasiveness and receptors involved, breast cancer is classified into various subtypes. The accurate diagnosis of breast cancer is important as it defines the prognosis and directs the type of treatment required. A number of major signaling pathways involved in breast tumorigenesis and its development include estrogen receptors (ERs), HER2, Wnt/β-catenin, Notch, Hedgehog (Hh), PI3K and mTOR pathway. Furthermore, certain enzymes like Cyclin dependent kinases and breast tumor kinases also play a vital role in cell cycle regulation and therefore, in the development of breast neoplasms. Recent studies have also enlightened the role of non-coding RNAs in breast cancer development. This review discusses various aspects of breast cancer such as its etiology, subtypes, various signaling pathways involved, targets projected by these pathways and the current treatment options based on a few of these targets. Also, the role of different genes, enzymes and non-coding RNAs related to breast tumorigenesis and development is discussed.
Full text article
References
Allison, K. H. 2012. Molecular Pathology of Breast Cancer: What a Pathologist Needs to Know. American Journal of Clinical Pathology, 138(6):770–780.
American Cancer Society 2019. Breast Cancer Facts and Figures 2019-2020. pages 1–44.
Carballo, G. B., Honorato, J. R. 2018. A highlight on Sonic hedgehog pathway. Cell Communication and Signaling, 16:11.
Chen, J. K. 2002. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes and Development, 16(21):2743–2748. ISSN: 0890-9369.
Chi, D., Singhala, H. 2019. Estrogen receptor signaling is reprogrammed during breast tumorigenesis. PNAS, 116:11437–11443.
Chlebowski, R. T., Rohan, T. E. 2015. Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone Analyses of Data From 2Women’s Health Initiative Randomized Clinical Trials. JAMA Oncology, 1(3):296–305.
Colditz, G. A., Kaphingst, K. A., Hankinson, S. E., Rosner, B. 2012. Family history and risk of breast cancer: nurses’ health study. Breast Cancer Research and Treatment, 133(3):1097–1104. ISSN: 0167-6806, 1573-7217.
Davis, C., Tami, P. 2020. Body image in older breast cancer survivors: A systematic review. Psycho-Oncology, 29:823–832.
Dumbrava, I. 2018. Targeting gamma secretase: has progress moved up a Notch? Annals of Oncology, 29(9):1889–1891.
Dyrstad, S. W., Yan, Y., Fowler, A. M., Colditz, G. A. 2015. Breast cancer risk associated with benign breast disease: systematic review and meta-analysis. Breast Cancer Research and Treatment, 149(3):569–575. ISSN: 0167-6806, 1573- 7217.
Feng, Y., Spezia, M. 2018. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes and Diseases, 5:77–106.
Finn, R. S., Aleshin, A., Slamon, D. J. 2016. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers. Breast Cancer Research, 18(1). ISSN: 1465-542X.
Gaskin, K. M. 2017. Structural anatomy of the breast. University of Wollongong, Accessed on: July 16, 2018.
Girgert, R., Emons, G., Gründker, C. 2019. Estrogen Signaling in ERα-Negative Breast Cancer: ERβ and GPER. Frontiers in Endocrinology, 9:781–781. ISSN: 1664-2392.
Giuliano, A. E., Edge, S. B., Hortobagyi, G. N. 2018. Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer. Annals of Surgical Oncology, 25(7):1783–1785. ISSN: 1068-9265, 1534-4681.
Gonzalez-Angulo, A. M., Ferrer-Lozano, J. 2011. PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer. Molecular Cancer Therapeutics, 10(6):1093–1101.
Hilakivi-Clarke, L. 2014. Maternal exposure to diethylstilbestrol during pregnancy and increased breast cancer risk in daughters. Breast Cancer Research, 16(2):208–218. ISSN: 1465-5411, 1465- 542X.
Iqbal, N., Iqbal, N. 2014. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Molecular Biology International, 2014:1–9. ISSN: 2090-2182, 2090-2190.
Jamdade, V. S., Sethi, N., Mundhe, N. A., Kumar, P., Lahkar, M., Sinha, N. 2015. Therapeutic targets of triple-negative breast cancer: a review. British Journal of Pharmacology, 172(17):4228– 4237. ISSN: 0007-1188.
Janku, F. 2017. Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients. Cancer Treatment Reviews, 59:93– 101. ISSN: 0305-7372.
Juliano, R. L. 2020. Addressing cancer signal transduction pathways with antisense and siRNA oligonucleotides. NAR Cancer, 2(3):1–14. ISSN: 2632-8674.
Larionov, A. A. 2018. Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients. Frontiers in Oncology, 8:89. ISSN: 2234-943X.
MacDonald, B. T., Tamai, K., He, X. 2009. Wnt/β- Catenin Signaling: Components, Mechanisms, and Diseases. Developmental Cell, 17(1):9–26. ISSN: 1534-5807.
Manavathi, B., Dey, O., Gajulapalli, V. N. R., Bhatia, R. S., Bugide, S., Kumar, R. 2013. Derailed Estrogen Signaling and Breast Cancer: An Authentic Couple. Endocrine Reviews, 34(1):1–32. ISSN: 0163-769X, 1945-7189.
Mehrgou, A., Akouchekian, M. 2016. The importance of BRCA1 and BRCA2 genes mutations in breast cancer development. Medical Journal of the Islamic Republic of Iran, 30:69.
Meseure, D., Alsibai, K. D., Nicolas, A., Bieche, I., Morillon, A. 2015. Long Noncoding RNAs as New Architects in Cancer Epigenetics, Prognostic Biomarkers, and Potential Therapeutic Targets. BioMed Research International, 2015:1–14. ISSN: 2314-6133, 2314-6141.
Miah, S., Martin, A., Lukong, K. E. 2012. Constitutive activation of breast tumor kinase accelerates cell migration and tumor growth in vivo. Oncogenesis, 1(5):e11. ISSN: 2157-9024.
Mirkin, S. 2018. Evidence on the use of progesterone in menopausal hormone therapy. Climacteric, 21(4):346–354. ISSN: 1369-7137, 1473-0804.
Narod, S. A., Salmena, L. 2011. BRCA1 and BRCA2 mutations and breast cancer. Discovery Medicine, 12(66):445–453.
Nichols, H. B., Schoemaker, M. J. 2019. Breast Cancer Risk After Recent Childbirth: A Pooled Analysis of 15 Prospective Studies. Annals of Internal Medicine, 170(1):22–30.
O’toole, S. A., Beith, J. M. 2013. Therapeutic targets in triple negative breast cancer. Journal of Clinical Pathology, 0:1–13.
Polyak, K. 2007. Breast cancer: origins and evolution. Journal of Clinical Investigation, 117(11):3155–3163. ISSN: 0021-9738.
Sever, R., Brugge, J. S., Cantley, L. 2015. Signal Transduction in Cancer, Cold Spring Harbor Perspectives in Medicine. pages 1–21. Cold Spring Harbor Laboratory Press.
Sharma, D., Kumar, S., Narasimhan, B. 2018. Estrogen alpha receptor antagonists for the treatment of breast cancer: a review. Chemistry Central Journal, 12(1):107. ISSN: 1752-153X.
Siegel, R. L., Miller, K. D., Jemal, A. 2019. Cancer statistics. CA: A Cancer Journal for Clinicians, 69(1):7–34. ISSN: 0007-9235, 1542-4863.
Sun, Y. S., Zhao, Z. 2017. Risk Factors and Preventions of Breast Cancer. International Journal of Biological Sciences, 13(11):1387–1397.
Sung, H., Ferley, J. 2021. Cancer Statistics. Cancer Journal for Clinicians, (0):1–41.
Sutherland, R. L., Musgrove, E. A. 2004. Cyclins and Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 9(1):95–104. ISSN: 1083-3021.
Vidal, M., Pare, L., Prat, A. 2016. Molecular Classification of Breast Cancer, Management of Breast Diseases. pages 203–219, Switzerland. Springer International Publishing.
Walker, A. J., Wedam, S. 2016. FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2- Negative Metastatic Breast Cancer. Clinical Cancer Research, 22(20):4968–4972.
Xue, M., Zhang, K. 2019. Regulation of estrogen signaling and breast cancer proliferation by a ubiquitin ligase TRIM56. Oncogenesis, 8. Article 30.
Zhan, T., Rindtorff, N., Boutros, M. 2017. Wnt signaling in cancer. Oncogene, 36(11):1461–1473. ISSN: 0950-9232, 1476-5594.
Zhang, X., Li, X., Zhang, J. 2013. Current Status and Future Perspectives of PI3K and mTOR Inhibitor as Anticancer Drugs in Breast Cancer. Current Cancer Drug Targets, 13:175–187.
Zhang, Y., Wang, X. 2020. Targeting the Wnt/β-catenin signaling pathway in cancer. Journal of Hematology and Oncology, 13:165.
Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.